Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects

BACKGROUND: Modified vaccinia Ankara (MVA) is being developed as a safer smallpox vaccine and is being placed in the US Strategic National Stockpile (SNS) as a liquid formulation for subcutaneous (SC) administration at a dose of 1 × 10(8) TCID(50) in a volume of 0.5 mL. This study compared the safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Frey, Sharon E., Wald, Anna, Edupuganti, Srilatha, Jackson, Lisa A., Stapleton, Jack T., Sahly, Hana El, El-Kamary, Samer S., Edwards, Kathryn, Keyserling, Harry, Winokur, Patricia, Keitel, Wendy, Hill, Heather, Goll, Johannes B., Anderson, Edwin L., Graham, Irene L., Johnston, Christine, Mulligan, Mark, Rouphael, Nadine, Atmar, Robert, Patel, Shital, Chen, Wilbur, Kotloff, Karen, Creech, C. Buddy, Chaplin, Paul, Belshe, Robert B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. Published by Elsevier Ltd. 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533873/
https://www.ncbi.nlm.nih.gov/pubmed/26143613
http://dx.doi.org/10.1016/j.vaccine.2015.06.075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533873/
https://www.ncbi.nlm.nih.gov/pubmed/26143613
http://dx.doi.org/10.1016/j.vaccine.2015.06.075

Ejemplares similares